Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis

被引:1
|
作者
Li, Jin [1 ]
Li, Yajun [2 ]
Zeng, Ruolan [2 ]
Lin, Jingguan [1 ]
Zhong, Meizuo [3 ]
Liu, Xianling [4 ]
He, Yizi [2 ]
He, Junqiao [2 ]
Ouyang, Zhou [2 ]
Huang, Lijun [2 ]
Xiao, Ling [5 ]
Zhou, Hui [2 ]
机构
[1] Hunan Canc Hosp, Dept Comprehens Chemotherapy Daytime Chemotherapy, Changsha, Hunan, Peoples R China
[2] Hunan Canc Hosp, Dept Lymphoma & Hematol, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Sch Basic Med Sci, Dept Histol & Embryol, Changsha, Hunan, Peoples R China
关键词
extranodal natural killer/T-cell lymphoma; nasal type; chemotherapy courses; low-risk; L-ASPARAGINASE; T-CELL; STAGE IE; CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; GEMCITABINE; ETOPOSIDE; IIE; DEXAMETHASONE; MULTICENTER;
D O I
10.2147/TCRM.S254246
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: This retrospective study compared effectiveness between <= 4 cycles and >= 5 cycles of L-asparaginase/pegaspargase-based chemoradiation in newly diagnosed low-risk extranodal natural killer/T-cell lymphoma (ENKTL), nasal type classified according to the Prognostic Index of Natural Killer (PINK) lymphoma model. Patients and Methods: Patients were categorized into <= 4-cycle (2-4 chemotherapy cycles, n = 166) and >= 5-cycle groups (5-6 cycles, n = 86). Propensity score matching analysis was used to reduce potential confounding bias between the two groups. Treatment responses, adverse events, and survival outcomes between the two groups were analyzed. Results: No matter before or after matching (65 in the <= 4-cycle group, 65 in the >= 5-cycle group), response rates and survival outcomes were similar between the <= 4-cycle and >= 5-cycle groups. Incidences of grade 1-2 anemia and transaminase elevation were higher in the >= 5-cycle group. After matching, for stage IE disease, there were no differences in response rates and survival outcomes between the two groups. For stage IIE disease, the complete response rate was higher in the >= 5-cycle group (72.4% vs 92.6%, p = 0.049), and the 3-year overall survival (65.5% vs 85.2%, p = 0.024) and 3-year progression-free survival (58.6% vs 81.5%, p = 0.027) rates were significantly extended in the >= 5-cycle group. Conclusion: When chemoradiotherapy strategies with L-asparaginase/pegaspargase-based regimens are applied to modem low-risk ENKTL patients classified according to the PINK model, it may be better to moderately extend chemotherapy courses in patients with stage IIE disease.
引用
收藏
页码:1151 / 1163
页数:13
相关论文
empty
未找到相关数据